WO2016096936A1 - Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc - Google Patents

Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc Download PDF

Info

Publication number
WO2016096936A1
WO2016096936A1 PCT/EP2015/079912 EP2015079912W WO2016096936A1 WO 2016096936 A1 WO2016096936 A1 WO 2016096936A1 EP 2015079912 W EP2015079912 W EP 2015079912W WO 2016096936 A1 WO2016096936 A1 WO 2016096936A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
difluoro
dioxo
thiazinan
Prior art date
Application number
PCT/EP2015/079912
Other languages
English (en)
Inventor
Benjamin Fauber
Tammy LADDYWAHETTY
Olivier RENE
Original Assignee
F. Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F. Hoffmann-La Roche Ag
Priority to JP2017532658A priority Critical patent/JP2017537966A/ja
Priority to CN201580068854.6A priority patent/CN107108600A/zh
Priority to EP15819803.6A priority patent/EP3233849A1/fr
Publication of WO2016096936A1 publication Critical patent/WO2016096936A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention pertains to compounds that modulate the function of retinoid-receptor related orphan receptor RORc (RQRy) and use of such compounds for treatment of autoimmune diseases
  • T helper 17 cells are interleukin (IL)-17 secreting CD4+ T cells involved in pathogenesis of autoimmune diseases such as rheumatoid arthritis, irritable bowel disease, psoriasis, psoriatic arthritis and spondyloarthridities.
  • the retinoic acid-related orphan receptor ⁇ (RORy or RORc) is recognized as a transcription factor necessary for Thl7 cell differentiation.
  • RORc is an orphan member of the nuclear hormone receptor subfamily that includes RORa (RORa) and RORp (RORb). RORc controls gene transcription by binding to DNA as a monomer. Selective modulation of RORc has been proposed as a route to discovery and development of Thl7 cell-associated autoimmune diseases.
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p is from 0 to 3;
  • q is from 0 to 3;
  • a five membered heterocyclyl selected from:
  • A is:
  • W is: -CR b R c -; -0-; -S-; -S0 2 -; or -NR d -;
  • one of X 1 , X 2 , X 3 and X 4 is N and the others are CR e ; or two of X 1 , X 2 , X 3 and X 4 are N and the others are CR e ; or three of X 1 , X 2 , X 3 and X 4 are N and the other is CR e ; or each of X 1 , X 2 , X 3 and X 4 is CR e ;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently is: hydro gen; or Ci_ 6 aikyl which may be unsubstituted or substituted one or more times with halo;
  • R 7 and R 8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R 9 is independently:
  • each R 10 is independently:
  • R a is:
  • Ci_ 6 aikoxy Ci. 6 alkoxy-Ci. 6 alkyl
  • heterocyclyl moieties are each independently selected from oxetanyl
  • tetrahydrofuranyl tetrahydropyranyl
  • azetidinyl pyrrolidinyl and piperidinyl
  • heterocycyl moieties and C 3 . 6 cycloalkyl moieties each may be unsubstituted or substituted one or more times with R f ;
  • R b , R c , and R d each independent is:
  • R b and R c together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R e is independently:
  • Ci_ 6 alkyl moieties may be unsubstituted or substituted one or more times with halo
  • R f is: Ci_ 6 alkyl; halo; oxo; hydroxy; or
  • the invention also provides and pharmaceutical compositions comprising the compounds, methods of using the compounds, and methods of preparing the compounds.
  • Alkyl means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms.
  • “Lower alkyl” refers to an alkyl group of one to six carbon atoms, i.e. Ci-C 6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec -butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
  • Alkenyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, e.g. , ethenyl, propenyl, and the like.
  • Alkynyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, e.g. , ethynyl, propynyl, and the like.
  • Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
  • alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
  • Alkoxyalkyl means a moiety of the formula R a -0-R b -, where R a is alkyl and R b is alkylene as defined herein.
  • exemplary alkoxyalkyl groups include, by way of example, 2-methoxy ethyl, 3-methoxypropyl, 1 -methyl -2 -methoxyethyl, l-(2-methoxyethyl)-3-methoxypropyl, and l-(2- methoxyethyl)-3 -methoxypropyl.
  • Alkoxyalkoxy' means a group of the formula -O-R-R' wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkylcarbonyl means a moiety of the formula -C(0)-R, wherein R is alkyl as defined herein.
  • Alkoxycarbonyl means a group of the formula -C(0)-R wherein R is alkoxy as defined herein.
  • Alkylcarbonylamino means a group of the formula -R-C(0)-NR'- wherein R is alkyl and R' is hydrogen or alkyl.
  • Alkylcarbonylalkyl means a group of the formula -R-C(0)-R' wherein R is alkylene and R' is alkyl as defined herein.
  • Alkoxyalkylcarbonyl means a moiety of the formula -C(0)-R-R', wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkoxycarbonylalkyl means a group of the formula -R-C(0)-R wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkoxycarbonylamino means a moiety of the formula R-C(0)-NR'-, wherein R is alkoxy and
  • R' is hydrogen or alkyl as defined herein.
  • Alkoxycarbonylaminoalkyl means a moiety of the formula R-C(0)-NR'-R"-, wherein R is alkoxy, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
  • Alkoxycarbonylalkoxy means a group of the formula -0-R-C(0)-R' wherein R is alkylene and R' is alkoxy as defined herein.
  • Haldroxycarbonylalkoxy means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
  • Alkylaminocarbonylalkoxy means a group of the formula -0-R-C(0)-NHR' wherein R is alkylene and R' is alkyl as defined herein.
  • Dialkylaminocarbonylalkoxy means a group of the formula -0-R-C(0)-NR'R" wherein R is alkylene and R' and R" are alkyl as defined herein.
  • Alkylaminoalkoxy means a group of the formula -O-R-NHR' wherein R is alkylene and R' is alkyl as defined herein.
  • Dialkylaminoalkoxy means a group of the formula -O-R-NR'R' wherein R is alkylene and R' and R" are alkyl as defined herein.
  • Alkylsulfonyl means a moiety of the formula - S0 2 -R, wherein R is alkyl as defined herein.
  • Alkylsulfonylalkyl means a moiety of the formula -R'-S0 2 -R" where where R' is alkylene and R" is alkyl as defined herein.
  • Alkylsulfonylalkoxy means a group of the formula -0-R-S0 2 -R' wherein R is alkylene and R' is alkyl as defined herein.
  • Amino means a moiety of the formula -NRR' wherein R and R' each independently is hyrdogen or alkyl as defined herein. "Amino thus includes “alkylamino (where one of R and R' is alkyl and the other is hydrogen) and “dialkylamino (where R and R' are both alkyl.
  • Aminocarbonyl means a group of the formula -C(0)-R wherein R is amino as defined herein.
  • N-hydroxy-aminocarbonyl means a group of the formula -C(0)-NR-OH wherein R is hydrogen or alkyl as defined herein.
  • N-alkoxy-aminocarbonyl means a group of the formula -C(0)-NR-R' wherein R is hydrogen or alkyl and R' is alkoxy as defined herein.
  • “Ammocarbonylaminoalkyl” means a group of the formula R 2 N-C(0)-NR'-R"- wherein each R is independently hydrogen or alkyl, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
  • N-alkyl-aminocarbonyl means a group of the formula -C(0)-NH-R wherein R is alkyl as defined herein.
  • N-hydroxy-N-alkylaminocarbonyl means a group of the formula -C(0)-NRR' wherein R is alkyl as defined herein and R' is hydroxy.
  • N-alkoxy-N-alkylaminocarbonyl means a group of the formula -C(0)-NRR' wherein R is alkyl and R' is alkoxy as defined herein.
  • N,N-di-Ci. 6 alkyl-aminocarbonyl means a group of the formula -C(0)-NRR' wherein R and R' are alkyl as defined herein.
  • Aminosulfonyl means a group of the formula -S0 2 -NH 2 .
  • N-alkylaminosulfonyl means a group of the formula -S0 2 -NHR wherein R is alkyl as defined herein.
  • ⁇ , ⁇ -dialkylaminosulfonyl means a group of the formula -S0 2 -NRR' wherein R and R' are alkyl as defined herein.
  • Alkylsulfonylamino means a group of the formula -NR'-S0 2 -R wherein R id alkyl and R' is hydrogen or alkyl as defined herein.
  • N-(alkylsulfonyl)-aminoalkyl means a group of the formula -R-NH-S0 2 -R' wherein R is alkylene and R' is alkyl as defined herein.
  • N-(Alkylsulfonyl)aminocarbonyl means a group of the formula -C(0)-NH-S0 2 -R wherein wherein R is alkyl as defined herein.
  • N-(Alkylsulfonyl)-N-alkylaminocarbonyl means a group of the formula -C(0)-NR-S0 2 -R' wherein wherein R and R' are alkyl as defined herein.
  • N-Alkoxyalkyl-aniinocarbonyl means a group of the formula -C(0)-NR-R'-OR” wherein R is hydrogen or alkyl, R' is alkylene, and R" is alkyl as defined herein.
  • N-Hydroxyalkyl-aminocarbonyl means a group of the formula -C(0)-NR-R'-OH" wherein R is hydrogen or alkyl and R' is alkylene as defined herein.
  • Alkoxyamino means a moiety of the formula -NR-OR' wherein R is hydrogen or alkyl and R' is alkyl as defined herein.
  • Alkylsulfanyl means a moiety of the formula -SR wherein R is alkyl as defined herein.
  • Aminoalkyl means a group -R-R' wherein R' is amino and R is alkylene as defined herein.
  • aminoalkyl includes aminomethyl, aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like.
  • the amino moiety of “aminoalkyl” may be substituted once or twice with alkyl to provide
  • alkylaminoalkyl and “dialkylaminoalkyl” respectively.
  • alkylaminoalkyl includes
  • methylaminomethyl methylaminoethyl, methylaminopropyl, ethylaminoethyl and the like.
  • Dialkylaminoalkyl includes dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, N- methyl-N-ethylaminoethyl, and the like.
  • Aminoalkoxy means a group -OR-R' wherein R' is amino and R is alkylene as defined herein.
  • Alkylsulfonylamido means a moiety of the formula -NR'S0 2 -R wherein R is alkyl and R' is hydrogen or alkyl.
  • Aminocarbonyloxyalkyl or “carbamylalkyl” means a group of the formula -R-0-C(0)-NR'R" wherein R is alkylene and R', R" each independently is hydrogen or alkyl as defined herein.
  • Alkynylalkoxy means a group of the formula -O-R-R' wherein R is alkylene and R' is alkynyl as defined herein.
  • Aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
  • the aryl group can be optionally substituted as defined herein.
  • aryl moieties include, but are not limited to, phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxy
  • Arylsulfonyl means a group of the formula -S0 2 -R wherein R is aryl as defined herein.
  • Aryloxy means a group of the formula -O-R wherein R is aryl as defined herein.
  • Aralkyloxy means a group of the formula -O-R-R" wherein R is alkylene and R' is aryl as defined herein.
  • Carboxy or “hydroxycarbonyl”, which may be used interchangeably, means a group of the formula -C(0)-OH.
  • Cyanoalkyl means a moiety of the formula -R'-R", where R' is alkylene as defined herein and R" is cyano or nitrile.
  • Cycloalkyl means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Particular cycloalkyl are unsubstituted or substituted with alkyl. Cycloalkyl can optionally be substituted as defined herein. Unless defined otherwise, cycloalkyl may be optionally substitued with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino.
  • cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated (cycloalkenyl) derivatives thereof.
  • Cycloalkenyl means a cycloalkyl as defined herein that includes at least one double bond or unsaturation.
  • exemplary cycloalkenyl include cyclohexenyl, cyclopentenyl, cyclobutenyl and the like.
  • Cycloalkylalkyl means a moiety of the formula -R'-R", where R' is alkylene and R" is cycloalkyl as defined herein.
  • Cycloalkylalkoxy means a group of the formula -O-R-R' wherein R is alkylene and R' is cycloalkyl as defined herein.
  • Cycloalkylcarbonyl means a moiety of the formula -C(0)-R, wherein R is cycloalkyl as defined herein.
  • C3_ 6 cycloalkyl-Ci_ 6 alkyl-carbonyl means a moiety of the formula -C(0)-R, wherein R is cycloalkylalkyl as defined herein.
  • Cyanoalkylcarbonyl means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is cyano or nitrile.
  • N-Cyano-aminocarbonyl means a moiety of the formula -C(0)-NHR, wherein R is cyano or nitrile.
  • N-Cyano-N-alkyl-aminocarbonyl means a moiety of the formula -C(0)-NRR' -R, wherein R' is alkyl as defined herein and R is cyano or nitrile.
  • Cycloalkylsulfonyl means a group of the formula -S0 2 -R wherein R is cycloalkyl as defined herein.
  • Cycloalkylalkylsulfonyl means a group of the formula -S0 2 -R wherein R is cycloalkylalkyl as defined herein.
  • Forml means a moiety of the formula -C(0)-H.
  • Heteroaryl means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring.
  • the heteroaryl ring may be optionally substituted as defined herein.
  • heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzo thiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolin
  • Heteroarylalkyl or “heteroaralkyl” means a group of the formula -R-R' wherein R is alkylene and R' is heteroaryl as defined herein.
  • Heteroarylsulfonyl means a group of the formula -S0 2 -R wherein R is heteroaryl as defined herein.
  • Heteroaryloxy means a group of the formula -O-R wherein R is heteroaryl as defined herein.
  • Heteroaralkyloxy means a group of the formula -O-R-R" wherein R is alkylene and R' is heteroaryl as defined herein.
  • halo refers to a substituent fluoro, chloro, bromo, or iodo.
  • Haloalkyl means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen.
  • exemplary haloalkyls include -CH 2 C1,
  • Haloalkoxy means a moiety of the formula -OR, wherein R is a haloalkyl moiety as defined herein.
  • An exemplary haloalkoxy is difluoromethoxy.
  • Heterocycloamino means a saturated ring wherein at least one ring atom is N, NH or N-alkyl and the remaining ring atoms form an alkylene group.
  • Heterocyclyl means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur).
  • the heterocyclyl ring may be optionally substituted as defined herein.
  • Examples of heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, morpholinyl,
  • Heterocyclylalkyl means a moiety of the formula -R-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
  • Heterocyclyloxy means a moiety of the formula -OR wherein R is heterocyclyl as defined herein.
  • Heterocyclylalkoxy means a moiety of the formula -OR-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
  • Hydroalkoxy means a moiety of the formula -OR wherein R is hydroxyalkyl as defined herein.
  • Haldroxyalkylamino means a moiety of the formula -NR-R' wherein R is hydrogen or alkyl and R' is hydroxyalkyl as defined herein.
  • Haldroxyalkylaminoalkyl means a moiety of the formula -R-NR'-R" wherein R is alkylene, R' is hydrogen or alkyl, and R" is hydroxyalkyl as defined herein.
  • Haldroxycarbonylalkyl or “carboxyalkyl” means a group of the formula -R-(CO)-OH where R is alkylene as defined herein.
  • Haldroxycarbonylalkoxy means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
  • Haldroxyalkylcarbonyl means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is hydroxy.
  • Haldroxyalkyloxycarbonylalkyl or “hydroxyalkoxycarbonylalkyl” means a group of the formula -R-C(0)-0-R-OH wherein each R is alkylene and may be the same or different.
  • Hydroalkyl means an alkyl moiety as defined herein, substituted with one or more, for example, one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group.
  • Representative examples include, but are not limited to, hydroxymethyl,
  • Hydrocycloalkyl means a cycloalkyl moiety as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a hydroxy substituent. Representative examples include, but are not limited to, 2-, 3-, or 4-hydroxycyclohexyl, and the like.
  • a 1-oxo-ethyl group is an acetyl group.
  • Alkoxy hydroxyalkyl and "hydroxy alkoxyalkyl”, which may be used interchangeably, means an alkyl as defined herein that is substituted at least once with hydroxy and at least once with alkoxy.
  • Alkoxy hydroxyalkyl and “hydroxy alkoxyalkyl” thus encompass, for example, 2-hydroxy-3- methoxy-propan-l-yl and the like.
  • Rea'Or “ureido” means a group of the formula -NR'-C(0)-NR"R"' wherein R', R" and R'" each independently is hydrogen or alkyl.
  • “Carbamate” means a group of the formula -0-C(0)-NR'R" wherein R' and R" each
  • Carboxy means a group of the formula -0-C(0)-OH.
  • Sulfonamido means a group of the formula -S0 2 -NR'R" wherein R', R" and R'" each independently is hydrogen or alkyl.
  • cycloalkyl or heterocyclyl moiety means that such moiety may be unsubstituted (i.e., all open valencies are occupied by a hydrogen atom) or substituted with specific groups as related herein.
  • leaving group means the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions.
  • Examples of leaving groups include, but are not limited to, halogen, alkane- or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, acyloxy, and the like.
  • Module means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
  • “Disease” and “Disease state” means any disease, condition, symptom, disorder or indication.
  • “Inert organic solvent” or “inert solvent” means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, ⁇ , ⁇ -dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, ieri-butanol, dioxane, pyridine, and the like.
  • the solvents used in the reactions of the present invention are inert solvents.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound.
  • Protecting group means the group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Certain processes of this invention rely upon the protective groups to block reactive nitrogen and/or oxygen atoms present in the reactants.
  • the terms "amino-protecting group” and “nitrogen protecting group” are used interchangeably herein and refer to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures.
  • Exemplary nitrogen protecting groups include, but are not limited to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl
  • Solidvates means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H 2 0, such combination being able to form one or more hydrate.
  • Arthritis means a disease or condition that causes damage to joints of the body and pain associated with such joint damage. Arthritis includes rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
  • Respiratory disorder refers to, without limitation, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
  • COPD chronic obstructive pulmonary disease
  • Subject means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term "subject” does not denote a particular age or sex.
  • “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
  • the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
  • Treating" or “treatment” of a disease state includes, inter alia, inhibiting the disease state, i.e. , arresting the development of the disease state or its clinical symptoms, and/or relieving the disease state , i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • the atoms represented in the structures herein are intended to encompass all naturally occurring isotopes of such atoms.
  • the hydrogen atoms represented herein are meant to include deuterium and tritium
  • the carbon atoms are meant to include C 13 and C 14 isotopes.
  • One or more carbon atom(s) of a compound of the invention may be replaced by a silicon atom(s), and it is contemplated that one or more oxygen atom(s) of a compound of the invention may be replaced by a sulfur or selenium atom(s).
  • the invention provides compounds of formula I:
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p is from 0 to 3;
  • q is from 0 to 3;
  • a five or six membered heteroaryl selected from: pyrrolyl;
  • a five membered heterocyclyl selected from: pyrrolidinyl; oxazolidinyl;
  • A is:
  • W is: -CR b R c -; -0-; -S-; -S0 2 -; or -NR d -;
  • one of X 1 , X 2 , X 3 and X 4 is N and the others are CR e ; or two of X 1 , X 2 , X 3 and X 4 are N and the others are CR e ; or three of X 1 , X 2 , X 3 and X 4 are N and the other is CR e ; or each of X 1 , X 2 , X 3 and X 4 is CR e ;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently is: hydro gen; or Ci_ 6 alkyl which may be unsubstituted or substituted one or more times with halo;
  • R 3 and R 4 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 7 and R 8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R 9 is independently: d_ 6 alkyl
  • each R 10 is independently:
  • R a is:
  • heterocyclyl moieties are each independently selected from oxetanyl
  • tetrahydrofuranyl tetrahydropyranyl
  • azetidinyl pyrrolidinyl and piperidinyl
  • heterocycyl moieties and C 3 . 6 cycloalkyl moieties each may be unsubstituted or substituted one or more times with R f ;
  • R b , R c , and R d each independent is:
  • R b and R c together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R e is independently:
  • Ci_ 6 aikyl moieties may be unsubstituted or substituted one or more times with halo
  • R f is: Ci_ 6 aikyl; halo-Ci_ 6 aikyl; halo; oxo; hydroxy; or Ci_ 6 alkoxy.
  • m is 0.
  • m is 1.
  • n 0.
  • n is 1.
  • p is from 0 to 2
  • p is O or 1.
  • p is 0.
  • p is 1.
  • p is 2.
  • p is 3.
  • q is 1.
  • q is 2. In certain embodiments of formula I, q is 0 or 1.
  • q is 0, 1 or 2.
  • Het is a five or six membered heteroaryl selected from:
  • Het is : oxadiazolyl
  • Het is imidazolyl .
  • Het is pyrazolyl .
  • Het is isoxazolyl .
  • Het is oxazolyl .
  • Het is thiazolyl .
  • Het is oxadiazolyl .
  • Het is triazolyl
  • Het is tetrazolyl .
  • Het is thiophenyl .
  • Het is furanyl .
  • Het is pyridinyl .
  • Het is pyrimidinyl . In certain embodiments of formula I, Het is pyridazinyl .
  • Het is pyrazinyl .
  • Het is 3H-l,3,4-oxadiazol-2-one-5-yl.
  • Het is 2-hydroxymethyl-l,3,4-oxadiazol-5-yl. In certain embodiments of formula I, Het is a five membered heterocyclyl selected from:
  • Het is pyrrolidinyl
  • Het is oxazolidinyl.
  • Het is dioxolanyl
  • Het is imidazolidinyl.
  • A is:Ci_ 6 alkylene which may be unsubstituted or substituted once or twice with R a .
  • A is:Ci_ 6 alkenylene which may be unsubstituted or substituted once or twice with R a .
  • A is: methylene; or ethylene; each of which may be unsubstituted or substituted with R a .
  • A is: -CH 2 -; -C(CH 3 ) 2 -; -CHCH 3 -; or -CHR a -.
  • A is methylene which may be unsubstituted or substituted with R a .
  • A is ethylene which may be unsubstituted or substituted with R a .
  • A is methylene
  • A is ethylene
  • A is -CH 2 - -.
  • A is -CHCH 3 -.
  • A is -C(CH 3 ) 2 -.
  • A is -CHR a -.
  • W is -CR b R c - or -0-.
  • W is -CR b R c -.
  • W is -0-.
  • W is -NR d -. n certain embodiments of formula W is -S-.
  • n certain embodiments of formula W is -SO2-.
  • n certain embodiments of formula W is -CH 2 -.
  • n certain embodiments of formula X ⁇ X 2 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 1 is N and X 2 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 2 is N and X 1 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 1 and X 4 are N, and X 2 and X 3 are CR a .
  • n certain embodiments of formula X 2 and X 3 are N, and X 1 and X 4 are CR e .
  • n certain embodiments of formula X 1 and X 2 are N, and X 3 and X 4 are CR e .
  • R 1 is Ci_ 6 aikyl.
  • R 2 is Ci_ 6 aikyl.
  • R 3 is Ci_ 6 aikyl.
  • n certain embodiments of formula R 4 is Ci_ 6 aikyl.
  • R 5 is Ci_ 6 alkyl.
  • R 6 is Ci_ 6 aikyl.
  • n certain embodiments of formula R 7 is Ci_ 6 alkyl.
  • n certain embodiments of formula R 8 is Ci_ 6 aikyl.
  • R 3 and R 4 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 3 and R 4 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • R 5 and R 6 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 5 and R 6 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • R 7 and R 8 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 7 and R 8 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • one of R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached form a three, four, five, six or seven membered ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • each R 9 is independently: C h alky!; halo; or halo-
  • R 9 is Ci_ 6 alkyl.
  • R 9 is halo
  • R 9 is
  • R 9 is cyano
  • R 9 is halo-Ci_ 6 alkyl.
  • each R 9 is independently: fluoro; chloro; or trifluoromethyl.
  • R is: Ci_ 6 alkyl; hydroxy; oxo; or hydroxy-Ci.
  • R is hydroxy. In certain embodiments of formula I, R is oxo.
  • R 10 is cyano
  • R 10 is halo
  • R 10 is
  • R 10 is
  • R 10 is Ci_ 6 alkyl.
  • R 10 is halo-Ci_ 6 alkyl.
  • R 10 is cyano-Ci_ 6 alkyl.
  • R a is: C 3 . 6 cycloalkyloxy; C ⁇ ecycloalkyl-C ! ⁇ alkoxy; heterocylyl-C ! ⁇ alkyl; or heterocylyl-C ! ⁇ alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl,
  • heterocycyl moieties and C 3 _ 6 cycloalkyl each may be unsubstituted or substituted one or more times with R f .
  • R a is: Ci_ 6 alkoxy; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties each may be unsubstituted or substituted one or more times with R f .
  • R a is: Ci_ 6 alkoxy; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and azetidinyl.
  • R a is Ci_ 6 alkoxy.
  • R a isC ⁇ alkoxy-C ealkyl.
  • R a is
  • R a is C 3 . 6 cycloalkyl which may be unsubstituted or substituted one or more times with R f .
  • R a is C ⁇ cycloalkyl-CVealkyl wherein the C 3 _ 6 cycloalkyl moiety may be unsubstituted or substituted one or more times with R f .
  • R a is C 3 . 6 cycloalkyloxy; C ecycloalkyl-C ealkoxy; heterocyclyl; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C 3 . 6 cycloalkyl each may be unsubstituted or substituted one or more times with R f .
  • R a is C ⁇ cycloalkyl-CVealkoxy wherein the C 3 _ 6 cycloalkyl moiety may be unsubstituted or substituted one or more times with R f .
  • R a is heterocyclyl selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R a is heterocylyl-C ⁇ alkyl wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R a is heterocylyl-Ci_ 6 alkoxy wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R b is hydrogen
  • R b is Ci_ 6 alkyl.
  • R c is hydrogen
  • R c is Ci_ 6 alkyl.
  • R b and R c together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R b and R c together with one of R 7 and R 8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R b and R c together with one of R 5 and R 6 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R d is hydrogen
  • R d is d_ 6 alkyl.
  • each R e is independently: hydrogen; Ci_ 6 alkyl; halo; or cyano; wherein the Ci_ 6 alkyl moieties may be unsubstituted or substituted one or more times with halo;
  • each R e is independently: hydrogen; Ci_ 6 alkyl; halo; or halo-Ci_ 6 alkyl.
  • each R e is independently: hydrogen; Ci_ 6 alkyl; or halo.
  • each R e is independently: hydrogen; or halo. In certain embodiments of formula I each R e is independently: hydrogen; or fluoro. In certain embodiments of formula I R e is hydrogen.
  • R e is d_ 6 alkyl.
  • R e is halo
  • R e is C ! . 6 alkoxy.
  • R e is cyano
  • R e is halo-Ci -6 alkyl.
  • R f is: Ci_ 6 alkyl; halo; oxo; hydroxy; acetyl; or Ci_
  • R f is C h alky.
  • R f is halo
  • R is Ci_ 6 alkoxy.
  • R f is halo-Ci -6 alkyl.
  • R f is oxo
  • R f is hydroxy
  • R f is acetyl
  • R s is Ci_ 6 alkyl
  • R s is oxo
  • R s is halo
  • R s is halo-Ci_ 6 alkyl
  • R s is hydroxy-Ci_ 6 alkyl
  • R g is Ci_ 6 alkoxy-Ci_ 6 alkyl
  • R g is cyano-C ⁇ alkyl.
  • s is from 0 to 3
  • m, n, p, q, Het, A, W, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined herein.
  • R e is halo
  • R e is fluoro. In certain embodiments of formula II, s is 0 or 1.
  • s is 0.
  • s is 1.
  • s is 1 or 2.
  • s is 2.
  • s is 1, 2 or 3.
  • s is 2 or 3.
  • s is 3.
  • the subject compounds may be of formula II In c e of formula III:
  • the invention also provides a compound selected from [5-[[2,5-difluoro-4-[[(3S,6R)-3-me 1 ,l-dioxo-6-phenyl-tMazinan-2-yl]methyl]phenyl]m
  • the invention also provides a method for treating a disease or condition mediated by or otherwise associated with the RORc receptor, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
  • the disease may be arthritis such as rheumatoid arthritis or osteoarthritis.
  • the disease may be asthma or COPD.
  • the disease may be psoriasis.
  • the disease may be muscular distrophy.
  • the starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagentsor Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplemental; and Organic Reactions , Wiley & Sons: New York, 1991, Volumes 1-40.
  • the following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
  • the starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
  • the reactions described herein may be conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, for example, from about 0 °C to about 125 °C, or conveniently at about room (or ambient) temperature, e.g., about 20 °C.
  • Scheme A illustrates one synthetic procedure usable to prepare specific compounds of formula I, wherein LG is a leaving group such as halo, sulfonate, or the like, and m, n, p, q, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R b and R c are as defined herein.
  • LG is a leaving group such as halo, sulfonate, or the like
  • m, n, p, q, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R b and R c are as defined herein.
  • step 1 of Scheme A alkyl amine a is reacted with benzyl sulfonyl chloride b to form sulfonamide compound c.
  • the reaction of step 1 may be carried out in a polar aprotic solvent such as THF or methylene chloride, and in the presence of a tertiary amine base or weak base such as potassium carbonate.
  • the leaving group of compound a may be bromo in certain embodiments.
  • the chloro group of compound b may in certain embodiments be replaced by other halo or leaving group.
  • a cyclization reaction is carried out in step 2 to afford thiazinane compound d.
  • the cyclization may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent under anhydrous conditions.
  • step 3 thiazinane compound c is reacted with aryalkyl halide compound e to yield aralkyl thiazinane f.
  • the reaction of step 3 may be carried out in the presence of a strong base such as sodium hydride under anhydrous polar aprotic solvent conditions.
  • the bromo groups of compound e may be replaced by other suitable leaving groups used in the art.
  • Thiazinane compound f may then be reacted with oxoethyl zinc halide reagent g in step 4 to provide ester compound h.
  • This reaction may be carried out in the presence of suitable palladium catalyst under polar aprotic conditions in a solvent such as dry tetrahydrofuran.
  • step 5 ester compound h is reacted with hydrazine to yield the corresponding hydrazide compound i.
  • step 6 hydrazide compound is reacted with acyl halide reagent j to afford an acyl hydrazide compound k.
  • step 7 a cyclization is carried out to form an oxadiazole group, resulting in the compound 1, whihch is a compound of formula I in accordance with the invention.
  • reagent g may be replaced by the corresponding thionoester to provide a thiadiazole group in the final compound.
  • the group R a may be replaced by an alkyl group, or may omitted from reagent g and introduced (if desired) in a later step.
  • the group R 10 may omitted from acyl reagent j and, if desired, introduced in a later step.
  • step 1 of Scheme B tri-(tert-butyl)-slilyloxy amine m is reacted with benzyl sulfonyl chloride b, as described above with reference to Scheme A, to form sulfonamide compound n.
  • the tri-(tert-butyl)-slilyloxy group may be replaced with other leaving groups.
  • step 2 sulfonamide compound n is reacted with iodochloromethane to provide an alkenylsulfonamide compound o. This reaction may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent such as THF under anhydrous conditions.
  • iodochloromethane may be replaced with other methylene reagents.
  • step 3 a cyclization reaction is affected to provide oxathiazepane compound p.
  • the cyclization may be carried out in the presence of an amine base under polar aprotic solvent conditions.
  • step 4 oxathiazepane compound p is reacted with aryalkyl halide compound e to yield aralkyl oxathiazepane compound q, in the manner described above with reference to Scheme A.
  • Steps 5-8 may then be carried out in the manner described above for steps 4-7 of Scheme A. Briefly, oxathiazepane compound q is reacted with zinc halide reagent g in step 5 to provide ester compound r, which is then reacted with hydrazine in step 6 to give the corresponding hydrazide compound s. Hydrazide compound s may then b acylated in step 7 to make compound t, followed by ring closure in step 8, to afford sultam compound u, which is a compound of formula I in accordance with the invention.
  • the invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a
  • the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, for example 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
  • One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
  • Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • a particular manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
  • a compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages.
  • the pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
  • Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the invention may be formulated in a wide variety of oral administration dosage forms.
  • the pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component.
  • the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
  • the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets may contain from about one (1) to about seventy (70) percent of the active compound.
  • Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
  • liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
  • Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
  • Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
  • Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
  • Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • the compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the compounds of the invention may be formulated for administration as suppositories.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
  • the compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the subject compounds may be formulated for nasal administration.
  • the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
  • the formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
  • the compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
  • the compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example,
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by a metered valve.
  • the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
  • formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
  • the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.
  • Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support.
  • the compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one).
  • Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection.
  • the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
  • the pharmaceutical preparations may be in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the compounds of the invention are useful for treatment of immune disorders generally.
  • the compounds may be used for treatment of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
  • the compounds may be used for treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • the compounds may be used for treatment of gastrointestinal disorder ("GI disorder”) such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
  • GI disorder such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
  • the compounds may be used for treatment of psoriasis, muscular sclerosis, Sjogren' s disease, lupus, and pulmonary fibrosis.
  • Method A Compounds were analysed using the following conditions: Experiments were performed on a Waters ZMD single quadrupole mass spectrometer linked to a Hewlett Packard HP 1100 LC system with UV diode array detector and 100 position autosampler. The spectrometer has an electrospray source operating in positive and negative ion mode. This system uses a Phenomenex Luna 3 ⁇ CI 8(2) 30 x 4.6 mm column at ambient temperature and a 2.0 mL / minute flow rate.
  • the initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.5 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. This was maintained for 1 minute before returning to 95% solvent A and 5% solvent B over the next 0.5 minute. Total run time was 6 minutes.
  • Method B Compounds were analysed using the following conditions: Experiments were performed on a Waters Micromass ZQ2000 quadrupole mass spectrometer linked to a Waters Acquity UPLC system with a PDA UV detector.
  • the spectrometer has an electrospray source operating in positive and negative ion mode. This system uses an Acquity BEH C18 1.7 ⁇ 100 x 2.1 mm column, maintained at 40 °C or an Acquity BEH Shield RP18 1.7 ⁇ 100 x 2.1 mm column, maintained at 40 °C and a 0.4 mL / minute flow rate.
  • the initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.4 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 5.6 minutes. This was maintained for 0.8 minute before returning to 95% solvent A and 5% solvent B over the next 1.2 minutes. Total run time was 8 minutes.
  • 3 ⁇ 4 NMR spectra were recorded at ambient temperature or at 80 °C where indicated using one of the following machines: Varian Unity Inova (400 MHz) spectrometer with a triple resonance 5mm probe, Bruker Avance DRX 400 (400 MHz) spectrometer with a triple resonance 5mm probe, a Bruker Avance DPX 300 (300 MHz) equipped with a standard 5mm dual frequency probe for detection of 1H and 13C, Bruker Fourier 300MHz system equipped with a standard 5mm 1H / 13C probe, a Bruker AVIII (400 MHz) using a BBI Broad Band Inverse 5mm probe, or a Bruker AVIII (500 MHz) using a QNP (Quad Nucleus detect) 5mm probe.
  • Varian Unity Inova 400 MHz
  • Bruker Avance DRX 400 400 MHz
  • a triple resonance 5mm probe a Bruker Avance DPX 300 (300 MHz) equipped with a standard 5mm
  • Microwave reactions were carried out using a Biotage® Initiator® in vials appropriate to the scale of the reaction and at the temperature and time described in the experimental details.
  • Reverse Phase High Pressure Liquid Chromatography was used to purify compounds where indicated. Separation using gradient elution on a Phenomenex Gemini C18 column (250 x 21.2 mm, 5 micron) as stationary phase and using mobile phase indicated, operating at a 18 mL/min flow rate using a Gilson UV/Vis -155 dual channel detector and Gilson GX-271 automated liquid handler.
  • Phase separator cartridges are supplied by Biotage® as Isolute® phase separator cartridges.
  • Step 2 Benzyl jV-i(2,S')-4-hydroxybutan-2-yllcarbamate and Benzyl jV-i(2R)-4-hydroxybutan-2- yllcarbamate
  • a solution of 3-[[(benzyloxy)carbonyl]amino]butanoic acid (102 g, 429.92 mmol, 1.00 equiv) in THF (300 mL)
  • BH 3 /THF ( IN) (645 mL, 1.50 equiv) dropwise with stirring at 0-5°C.
  • Step 1 (R)-3-(Phenylmethylsulfonamido)butyl phenylmethanesulfonate
  • Step 2 (R)-A/-(4-Chlorobutan-2-yl)-l -phenylmethanesulfonamide
  • a ⁇ -(2-bromoethyl)(4-fluorophenyl)methanesulfonamide was also made using the above procedure, replacing phenylmethanesulfonyl chloride with 4-fluoro-phenylmethanesulfonyl chloride.
  • 3 ⁇ 4 NMR 300 MHz, CDC1 3 ) ⁇ 7.43-7.38 (m, 2H), 7.13-7.07 (m, 2H), 4.62 (br s, IH), 4.26 (s, 2H), 3.41-3.32 (m, 4H).
  • a ⁇ -(3-bromopropyl)(4-fluorophenyl)methanesulfonamide was prepared using the above procedure.
  • H NMR 300 MHz, CDC1 3 ) ⁇ 7.42-7.37 (m, 2H), 7.13-7.07 (m, 2H), 4.26 (m, IH), 4.24 (s, 2H), 3.46-3.42 (m, 2H), 3.20-3.16 (m, 2H), 2.05-2.00 (m, 2H).
  • Step 1 A/-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylmethanesulfonamide
  • Step 2 jV-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylethenesulfonamid
  • Step 1 (3 ⁇ ,6R -2-(4-Bromo-2,5-difluorobenzyl -3-methyl-6-phenyl-l,2-thiazinane 1,1-dioxide
  • Step 2 ferf-Butyl 2 2,5-difluoro-4-rr(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
  • Step 3 Methyl 2-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
  • Step 4 Methyl 2-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanoate
  • Step 5 2- r2,5-Difluoro-4- [ r(3S,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanehydrazide
  • Step 6 5-r i-r2,5-Difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- 3 /-l,3,4-oxadiazol-2-one
  • reaction mixture was directly purified by reverse-phase preparative HPLC to give 5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3H-l,3,4-oxadiazol-2-one (91 mg, 0.20 mmol, 47% yield).
  • Step 1 r2,5-Difluoro-4-((3S,6R)-3-methyl J-dioxo-6-phenyl 1ambda*6* 1,21thiazinan-2-ylmethyl)- phenyll -acetic acid
  • Step 2 N-( 2-r2,5-Difluoro-4-((3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- lmethvD-phenyll -acetyl I -hydrazinecarboxylic acid tert-butyl ester
  • Step 3 r2,5-Difluoro-4-((3 t S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl)- hen yll -acetic acid hvdrazide
  • Step 4 5-r2,5-Difluoro-4-((3 ⁇ 6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21-thiazinan-2-lmethyl)- benzyl)-3H-
  • Step 1 Acetic acid 2-(N-[2-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,21thiazinan-2-ylmethyl)-phenyll -acetyl I -hydrazino)-2-oxo-ethylester
  • Step 3 f5-r2,5-Difluoro-4-((3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-benzyll-[l,3,41oxadiazol-2-yl)methanol
  • Step 1 r2,5-Difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyL ⁇
  • Step 3 Diazo-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethvD-phenyll -acetic acid methyl ester To a stirred solution of the product from Step 2 (0.360 g, 0.85 mmol) and
  • Step 4 r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyll-oxetan-3-yl-acetic acid methyl ester
  • Step 5 r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyl! -oxetan-3-yl-acetic acid hvdrazide
  • Step 6 5-f (R -r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-phenyl1-oxetan-3-yl-methyli-3H-ri,3,41oxadiazol-2-one and 5-f (S)-r2,5-difluoro-4-((3S,6R)- 3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,21thiazinan-2-ylmethyl)-phenylloxetan-3-yl-methyl
  • Examples 7 and 8 5-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-l,3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S , ,6 t S , -3-methyl-
  • Step 1 Methyl 2-(2,5-difluoro-4-(((3,S , -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl -2-methylpropanoate
  • Step 2 2-(2,5-Difluoro-4-(((3 t S , -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methvnphenvn-2- methylpropanehydrazide
  • step 1 The product from step 1 was reacted as described in example 1 step 5 to give the title compound.
  • LCMS (ESI): m/z 452 [M+H] + .
  • Step 3 5-(2-(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-L3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S , ,6 t S , -3-methyl- l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methyl phenyl propan-2-yl -l,3,4-oxadiazol-2(3H)-one
  • Example 9 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3-methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 ,2-dihvdro-3//-pyrazol-3 -one
  • Step 1 2-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDacetic acid
  • Step 2 Methyl 4-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)-3-oxopentanoate
  • Step 3 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l,2-dihvdro-3H-pyrazol-3-one
  • step 2 To a solution of the product of step 2 (75 mg, 0.16 mmol) in methanol (0.5 mL) was added hydrazine hydrate (0.04 mL, 0.8 mmol) and the solution was stirred at 60 °C for 2 h. The reaction mixture was then purified by preparative HPLC to give the title compound (9 mg, 0.020 mmol, 12% yield).
  • Example 10 3-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)hydrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2,4-dihvdro-3//- 1 ,2,4-triazol-3-one
  • Example 12 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDpropanoyl)- jV-methylhydrazine- 1 -carboxamide
  • Step 2 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-4-methyl-2,4-dihydro-3H-l,2,4-triazol-3-one
  • step 1 The product of step 1 was reacted as described in example 5 step 2 to give the title compound. : H
  • Example 13 5-(1-(2,5- ⁇ 1 ⁇ -4-(((3 ⁇ ,6/? -3- ⁇ 6 ⁇ 1 ⁇ 1-1,1-(1 ⁇ -6- ⁇ 1 ⁇ 6 ⁇ 1-1,2-11 ⁇ -2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-thiazinan-2- yl)methyl)phenyl)propanoyl)- 1 -methylhydrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl ethyl -2-methyl-2,4-dihvdro-3 /-l,2,4-triazol-3-one
  • step 1 The product of step 1 was reacted as described in example 5 step 2 to give the title compound.
  • Example 14 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)-2-methylhvdrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 -methyl- 1 ,2-dihydro-3/f- 1 ,2,4-triazol-3-one
  • Step 1 4-(2,5-Difluoro-4-(((3S,6R)-3-methyl-l,l-dioxido-6 ⁇
  • Step 2 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)isoxazol-3(2 /)-one
  • step 1 The product of step 1 (150 mg, 0.31 mmol) was dissolved in MeOH (5 mL) and cone. HC1 (1.5 mL). The reaction was stirred at 80 °C for 2 h. Upon cooling, the mixture was diluted with water, extracted with f-PrOAc (x3), dried over MgS0 4 , filtered, and purified by preparative HPLC to give the title compound (93.5 mg, 65% yield).
  • Example 16 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
  • Example 18 2-(5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetonitrile
  • Example 20 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2,2,2-trifluoroethyl)-l,3,4-oxadiazol-2(3 f)-one
  • Example 22 2-(5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetamide 5-[l-[2,5-Difluoro-4 [(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2-bromoacetamide, as described in example 11, to give the title compound.
  • Example 23 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2-methoxyethyl)-l,3,4-oxadiazol-2(3H)-one
  • Example 24 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylisoxazol-3(2 /)-one and (3S,6R)-2-(2,5-difluoro-4-( l-(3- methoxyisoxazol-5-yl)ethyl)benzyl)-3-methyl-6-phenyl-l,2-thiazinane 1,1 -dioxide
  • Example 25 3 - ⁇ 1 -r2,5-Difluoro-4- IT(3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2-
  • Step 1 jV-(l-(4-(((ferf-Butyldimethylsilyl)oxy)methyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2- sulfinamide
  • Step 2 /V-(l-(2,5-Difluoro-4-(hvdroxymethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 3 jV-(l-(4-(Chloromethyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 4 N-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • step 3 To a solution of the product of step 3 (3.4 g, 11 mmol) in DMF (50mL) was added (35,6R)-3- methyl-6-phenyl-thiazinane 1,1-dioxide (2.9 g, 13 mmol) and cesium carbonate (12.4 g, 38 mmol). The reaction was stirred at 25 °C for 16 h, quenched with saturated NH 4 C1 solution (100 mL), extracted with EtOAc (50mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • Step 5 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethan- 1 -aminium chloride
  • step 4 To a solution of the product of step 4 (4.6 g, 9.2 mmol) in MeOH (20 mL) was added dropwise anhydrous HC1 in 1,4-dioxane (4 M, 6.9 mL, 27.7 mmol) at 0 °C. The reaction was stirred at 0 °C for 30 min. The solvent was removed in vacuo and the crude product was triturated with diethyl ether, filtered, washed with more diethyl ether, dried under a high vacuum system for 1 h to give the title compound (3.8 g, 96% yield) as a white solid.
  • Step 6 /V-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l /-imidazole-l-carboxamide
  • Step 7 3-ri-r2,5-difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- l /-imidazol-2-one
  • Example 26 l-ri-r2,5-Difluoro-4-rr(3,S , ,6R -3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-
  • Step l N-(l-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-tMazinan-2 ⁇
  • Step 2 Methyl ⁇ -cyano- ⁇ -(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)glvcinate
  • step 1 To a solution of the product of step 1 (100 mg, 0.24 mmol) in THF (10 mL) was added NaH (60%, 10.4 mg, 0.26 mmol), the reaction mixture was stirred at 0 °C for 1 h, and then methyl 2- bromoacetate (36 mg, 0.24 mmol) was added, the reaction mixture was stirred at 25 °C for 16 h. The reaction was quenched with H 2 0 (2 mL), extracted with EA (2 x 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • Step 3 1 - ⁇ 1 - r2,5-Difluoro-4-r ⁇ (3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHimidazolidine-2,4-dione
  • Step 1 (3S,6R)-2-(4-( l-Ethoxyvinyl)-2,5-difluorobenzyl)-3-methyl-6-phenyl- 1 ,2-thiazinane 1 , 1 -dioxide
  • Step 2 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethan- 1 -one
  • Step 3 (3£,6R -2-(2,5-Difluoro-4-(l-hydroxyethyD 1,1-dioxide
  • Step 4 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl methanesulfonate
  • step 3 To a solution of the product of step 3 (800 mg, 2.0 mmol) in DCM (40 mL) at 0 °C was added NEt 3 (0.84 mL, 6.1 mmol), and then added dropwise methanesulfonyl chloride (0.31 mL, 4.1 mmol). The mixture was stirred at 15 °C for 2 h, then quenched with saturated NaHC0 3 (20 mL), extracted with DCM (2x30mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product as light yellow oil which was used in the next step without further purification.
  • LCMS (ESI): m/z 496.1 [M+Na] + .
  • Step 5 fert-Butyl 2-(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethvDhydrazine- 1 -carboxylate
  • step 4 To a solution of the product of step 4 (500 mg, 1.1 mmol) in acetonitrile (30 mL) was added tert- butyl hydrazinecarboxylate (277 mg, 2.1 mmol) and Cs 2 C0 3 (1 g, 3.1 mmol). The mixture was stirred at
  • Step 6 fert-Butyl 2-carbamoyl-2-(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2- thiazinan-2-yl)methyl)phenyl)ethyl)hydrazine- 1 -carboxylate
  • step 5 To a solution of the product of step 5 (120 mg, 0.24 mmol) in DCM (10 mL) was added triethylamine (0.1 mL, 0.71 mmol) at 0 °C, then bis(trichloromethyl) carbonate (22.8 mg, 0.08 mmol) in DCM (10 mL) was added triethylamine (0.1 mL, 0.71 mmol) at 0 °C, then bis(trichloromethyl) carbonate (22.8 mg, 0.08 mmol) in
  • Step 8 2-r i-r2,5-Difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvH-4ff-l,2,4-triazol-3-one
  • step 7 To a solution of lthe product of step 7 (100 mg, 0.22 mmol) was added triethoxymethane (6.0 mL, 0.22 mmol), the reaction mixture was stirred at 85 °C for 6 h. The solvent was removed under reduced pressureand the residue was purified by Biotage Flash column (12 g silica, UV254,
  • Step 1 ferf-Butyl ((ferf-butoxycarbonyl)oxy)(l-(2,5-difluoro-4-(((3 ⁇ ,6R)-3-methyl-l,l-dioxido-6-phenyl- l,2-thiazinan-2-yl)methyl)phenyl)ethyl)carbamate
  • Step 2 ferf-Butyl (l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(hvdroxy)carbamate
  • Step 3 ferf-Butyl (l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(propioloyloxy)carbamate
  • step 2 the product of step 2 (80 mg, 0.16 mmol).
  • Step 4 2-ri-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHisoxazol-5-one
  • This assay was used to determine a compound's potency in inhibiting activity of RORc by determining, Ki app , IC 50 , or percent inhibition values. Consumables used in this Example are shown in Table 5 below.
  • NBS Nonspecific binding
  • 25-hydroxycholesterol (1 uM) was used to determine the level of NSB signal is prepared in DMSO as for compounds above, then diluted in Assay Buffer to give a final concentration of 5 uM.
  • 25-hydroxycholesterol in 25% DMSO/75% Assay Buffer 10 uL per well was used for NSB samples.
  • Wells for Total Binding and No Receptor sample determination contained 10 uL of 25% DMSO/75% Assay Buffer per well.
  • 25-[ 3 H]hydroxycholesterol was diluted in Assay Buffer to obtain 15 nM and vortex to mix. Add 20 uL to all wells to reach 6 nM final concentration in the assay.
  • the optimal concentration for RORc receptor was found to be 0.6 ug/mL.
  • Stock receptor solution was diluted in assay buffer to obtain 1.5 ug/mL in Assay Buffer. 20 uL was added to all wells.
  • Assay plates were 96-well polypropylene V-bottom plates. 10 uL of 5x compound in
  • Buffer was added to all wells. 20 uL of 1.5 ug/mL RORc receptor was added to wells (or 40 uL Assay Buffer to No R wells). Following addition to the wells, the plates were incubated 3 h at 25°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Les composés de la formule (I) : ou un sel pharmaceutique de celui-ci, dans laquelle m, n, p, q, Het, A, W, R1, R2, R3, R4, R5, R6, R7, R8, R et R10 tels que définis dans la description sont des modulateurs de récepteur orphelin associé au récepteur des rétinoïdes RORc (RORγ). L'invention concerne également des procédés d'élaboration de ces composés, ainsi que des méthodes consistant à utiliser ces composés pour traiter des maladies inflammatoires telles que l'arthrite.
PCT/EP2015/079912 2014-12-17 2015-12-16 Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc WO2016096936A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2017532658A JP2017537966A (ja) 2014-12-17 2015-12-16 ＲＯＲｃモジュレーターとしてのヘテロアリールアルキレンアリールスルタム誘導体
CN201580068854.6A CN107108600A (zh) 2014-12-17 2015-12-16 作为RORc调节剂的杂芳基亚烷基芳基磺内酰胺衍生物
EP15819803.6A EP3233849A1 (fr) 2014-12-17 2015-12-16 Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462093263P 2014-12-17 2014-12-17
US62/093,263 2014-12-17
US201562190119P 2015-07-08 2015-07-08
US62/190,119 2015-07-08

Publications (1)

Publication Number Publication Date
WO2016096936A1 true WO2016096936A1 (fr) 2016-06-23

Family

ID=55068972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/079912 WO2016096936A1 (fr) 2014-12-17 2015-12-16 Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc

Country Status (4)

Country Link
EP (1) EP3233849A1 (fr)
JP (1) JP2017537966A (fr)
CN (1) CN107108600A (fr)
WO (1) WO2016096936A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005668A1 (fr) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés comme modulateurs de rorc
WO2017005900A1 (fr) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés comme modulateurs de rorc
CN106748816A (zh) * 2016-11-30 2017-05-31 河南师范大学 一种度鲁特韦关键中间体(r)‑3‑氨基丁醇的合成方法
WO2017102796A1 (fr) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Dérivés d'hétéroarylamide sultame en tant que modulateurs de rorc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031330A1 (en) * 2012-07-11 2014-01-30 Genentech, Inc. ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2015104356A1 (fr) * 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés en tant que modulateurs de rorc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031330A1 (en) * 2012-07-11 2014-01-30 Genentech, Inc. ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2015104356A1 (fr) * 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés en tant que modulateurs de rorc

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005668A1 (fr) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés comme modulateurs de rorc
WO2017005900A1 (fr) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag Dérivés d'aryle sultame utilisés comme modulateurs de rorc
US10259808B2 (en) 2015-07-08 2019-04-16 Genentech, Inc. Aryl sultam derivatives as RORc modulators
WO2017102796A1 (fr) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Dérivés d'hétéroarylamide sultame en tant que modulateurs de rorc
CN106748816A (zh) * 2016-11-30 2017-05-31 河南师范大学 一种度鲁特韦关键中间体(r)‑3‑氨基丁醇的合成方法

Also Published As

Publication number Publication date
EP3233849A1 (fr) 2017-10-25
CN107108600A (zh) 2017-08-29
JP2017537966A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
EP2872504B1 (fr) Dérivés aryl sultames en tant que modulateurs de rorc
EP3092238B1 (fr) Dérivés d'aryle sultame utilisés en tant que modulateurs de rorc
EP3092239B1 (fr) Dérivés d'aryle sultame utilisés en tant que modulateurs de rorc
JP2016510781A (ja) ＲＯＲｃモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体
EP3233849A1 (fr) Dérivés d'aryle sultame hétéroarylalkylène utilisés en tant que modulateurs de rorc
EP3010919B1 (fr) Dérivés d'aryle sultame utilisés en tant que modulateurs de ror-c
EP3044224A1 (fr) Dérivés de céto-imidazopyridine en tant que modulateurs de rorc
EP3319962B1 (fr) Dérivés d'aryle sultame utilisés comme modulateurs de rorc
WO2017005668A1 (fr) Dérivés d'aryle sultame utilisés comme modulateurs de rorc
WO2017102796A1 (fr) Dérivés d'hétéroarylamide sultame en tant que modulateurs de rorc
JP2017502070A (ja) ＲＯＲｃモジュレーターとしてのヘテロアリールスルタム誘導体
EP3292117B1 (fr) Dérivés de pyridazine utilisés en tant que modulateurs de rorc
EP3292111A1 (fr) DÉRIVÉS DE PYRIDAZINE EN TANT QUE MODULATEURS DE RORc
WO2016177760A1 (fr) Dérivés de pyridazine utilisés en tant que modulateurs de rorc

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15819803

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2015819803

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017532658

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE